85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant Vaccine now in large scale production highlighting rapid response capability of novel FDA licensed cell culture technology 135 confirmed cases and 45 deaths from H7N9 virus since emergence in March according to the World Health […]
Approach Selectively Represses Only the Disease-Causing Gene Resulting in Statistically Significant Effects on Symptoms and Other Biomarkers of Disease in Animal Models RICHMOND, Calif., Nov. 12, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that positive preclinical data from their joint program with Shire plc to develop a novel ZFP Therapeutic® approach to Huntington’s disease (HD) were presented […]
E3 Grant Program helps health care institutions improve effectiveness, efficiency and excellence DUBLIN, Ohio, Nov. 11, 2013 /PRNewswire/ — The Cardinal Health Foundation is currently accepting applications for grant funding to help U.S., Canadian and Puerto Rican hospitals, health systems, community health clinics and other non-profit health care institutions improve the efficiency and quality of […]
GREENSBORO, N.C. – BUSINESS WIRE – Merz Pharma Group (Frankfurt am Main) announced that it has entered into a definitive agreement to acquire Anteis S.A., a Swiss company which specializes in the development, manufacture and commercialization of medical devices in the area of aesthetics. With products available in more than 90 countries on five continents, Anteis has been recognized as […]
Spain-based Grifols to acquire Novartis blood transfusion diagnostics unit for USD 1.675 billion Divestiture further enhances Novartis focus on strategic businesses Basel, November 11, 2013 – Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for USD 1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed […]
NEW YORK–November 11, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) today announced that Robert Bailey was appointed Senior Vice President, Chief Legal Officer General Counsel. In this role, Bailey will be responsible to manage the legal affairs of the Company, and will also serve as the company’s Corporate Secretary. Bailey will report to Brent Saunders, Chief Executive […]
UCLA Researchers Evaluate Long-term Outcomes of More than 1,000 Patients from Multiple Institutions SUNNYVALE, Calif., November 7, 2013 – Accuray Incorporated (Nasdaq: ARAY), announced today the publication of two papers stemming from a large multi-center study of CyberKnife® stereotactic body radiotherapy (SBRT) led by investigators at the University of California, Los Angeles (UCLA). The first […]
Second stage of CLL11 study showed Gazyva plus chlorambucil significantly reduced the risk of disease worsening or death by 61% compared to MabThera/Rituxan plus chlorambucil for people with previously untreated chronic lymphocytic leukemia Updated data from Stage 1a of CLL11 showed Gazyva plus chlorambucil improved overall survival compared to chlorambucil alone Full CLL11 study results […]
NEW YORK–November 7, 2013–(BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd. (collectively, “Forest”) announced today that they have entered into a settlement agreement with Actavis, Inc. and related companies and subsidiaries thereof, in patent infringement litigation brought by Forest in response to Actavis’s abbreviated new drug application (“ANDA”) seeking approval to market generic […]
Data Demonstrate ZFN-dependent CCR5 Modification of Long-lived Central Memory and Stem-like T-cells RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic® for HIV/AIDS. The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects […]